CURIOSITYSTREAM INC (CURI)

US23130Q1076 - Common Stock

1.53  +0.02 (+1.32%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CURI. CURI was compared to 72 industry peers in the Entertainment industry. The financial health of CURI is average, but there are quite some concerns on its profitability. CURI is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

CURI had negative earnings in the past year.
CURI had a positive operating cash flow in the past year.
CURI had negative earnings in each of the past 5 years.
CURI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CURI has a worse Return On Assets (-16.89%) than 78.87% of its industry peers.
CURI has a Return On Equity of -23.77%. This is comparable to the rest of the industry: CURI outperforms 40.85% of its industry peers.
Industry RankSector Rank
ROA -16.89%
ROE -23.77%
ROIC N/A
ROA(3y)-32.91%
ROA(5y)-33.84%
ROE(3y)-44.62%
ROE(5y)-54.51%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CURI has a Gross Margin (48.40%) which is in line with its industry peers.
CURI's Gross Margin has declined in the last couple of years.
CURI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15%
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

CURI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CURI has more shares outstanding than it did 1 year ago.
CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -2.54, we must say that CURI is in the distress zone and has some risk of bankruptcy.
CURI has a worse Altman-Z score (-2.54) than 81.69% of its industry peers.
CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -2.54
ROIC/WACCN/A
WACC9.16%

2.3 Liquidity

CURI has a Current Ratio of 1.90. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.90, CURI is in the better half of the industry, outperforming 70.42% of the companies in the same industry.
A Quick Ratio of 1.90 indicates that CURI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.90, CURI is in the better half of the industry, outperforming 73.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.00% over the past year.
Looking at the last year, CURI shows a decrease in Revenue. The Revenue has decreased by -8.56% in the last year.
Measured over the past years, CURI shows a quite strong growth in Revenue. The Revenue has been growing by 12.82% on average per year.
EPS 1Y (TTM)75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88%
Revenue 1Y (TTM)-8.56%
Revenue growth 3Y12.82%
Revenue growth 5YN/A
Sales Q2Q%-19.36%

3.2 Future

Based on estimates for the next years, CURI will show a very strong growth in Earnings Per Share. The EPS will grow by 25.98% on average per year.
The Revenue is expected to grow by 7.98% on average over the next years.
EPS Next Y76.97%
EPS Next 2Y38.68%
EPS Next 3Y25.53%
EPS Next 5Y25.98%
Revenue Next Year-13.04%
Revenue Next 2Y-2.56%
Revenue Next 3Y2.22%
Revenue Next 5Y7.98%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CURI. In the last year negative earnings were reported.
Also next year CURI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CURI indicates a rather cheap valuation: CURI is cheaper than 81.69% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CURI is valued a bit cheaper than 74.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 32.91
EV/EBITDA 4.04

4.3 Compensation for Growth

A more expensive valuation may be justified as CURI's earnings are expected to grow with 25.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y25.53%

4

5. Dividend

5.1 Amount

CURI has a Yearly Dividend Yield of 6.62%, which is a nice return.
The stock price of CURI dropped by -22.56% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 3.63, CURI pays a better dividend. On top of this CURI pays more dividend than 97.18% of the companies listed in the same industry.
CURI's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
Industry RankSector Rank
Dividend Yield 6.62%

5.2 History

CURI is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y38.68%
EPS Next 3Y25.53%

CURIOSITYSTREAM INC

NASDAQ:CURI (12/24/2024, 1:00:00 PM)

1.53

+0.02 (+1.32%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners7.54%
Inst Owner Change24.15%
Ins Owners4.93%
Ins Owner Change8.14%
Market Cap84.88M
Analysts82.22
Price Target2.81 (83.66%)
Short Float %0.88%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield 6.62%
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date03-14 2025-03-14 (0.025)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.89%
Min EPS beat(2)-76.49%
Max EPS beat(2)28.7%
EPS beat(4)2
Avg EPS beat(4)-12.94%
Min EPS beat(4)-76.49%
Max EPS beat(4)43.07%
EPS beat(8)2
Avg EPS beat(8)-52.32%
EPS beat(12)6
Avg EPS beat(12)-25.07%
EPS beat(16)9
Avg EPS beat(16)-13.98%
Revenue beat(2)0
Avg Revenue beat(2)-5.93%
Min Revenue beat(2)-9.67%
Max Revenue beat(2)-2.18%
Revenue beat(4)0
Avg Revenue beat(4)-5.55%
Min Revenue beat(4)-9.67%
Max Revenue beat(4)-2.03%
Revenue beat(8)3
Avg Revenue beat(8)-6.75%
Revenue beat(12)5
Avg Revenue beat(12)-4.17%
Revenue beat(16)7
Avg Revenue beat(16)11.31%
PT rev (1m)59.42%
PT rev (3m)103.7%
EPS NQ rev (1m)-33.35%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)5.97%
EPS NY rev (3m)-27.27%
Revenue NQ rev (1m)-3.34%
Revenue NQ rev (3m)-18.17%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-8.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.64
P/FCF 32.91
P/OCF 32.98
P/B 1.36
P/tB 3
EV/EBITDA 4.04
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.05
FCFY3.04%
OCF(TTM)0.05
OCFY3.03%
SpS0.93
BVpS1.12
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.89%
ROE -23.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.4%
FCFM 4.98%
ROA(3y)-32.91%
ROA(5y)-33.84%
ROE(3y)-44.62%
ROE(5y)-54.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.02%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion 38.56%
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -2.54
F-Score6
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)0.52%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88%
EPS Next Y76.97%
EPS Next 2Y38.68%
EPS Next 3Y25.53%
EPS Next 5Y25.98%
Revenue 1Y (TTM)-8.56%
Revenue growth 3Y12.82%
Revenue growth 5YN/A
Sales Q2Q%-19.36%
Revenue Next Year-13.04%
Revenue Next 2Y-2.56%
Revenue Next 3Y2.22%
Revenue Next 5Y7.98%
EBIT growth 1Y62.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.94%
EBIT Next 3Y27.14%
EBIT Next 5Y15.73%
FCF growth 1Y104.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.14%
OCF growth 3YN/A
OCF growth 5YN/A